Comprehensive Psychiatry
Volume 42, Issue 6 , Pages 494-497, November 2001

Insight and treatment outcome in obsessive-compulsive disorder

From the Butler Hospital and the Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center Durham, NC; Department of Psychiatry, Medical and Behavioral Sciences, University of South Carolina, Charleston, SC; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA; and the Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX.

Abstract 

To determine whether (1) insight in obsessive-compulsive disorder (OCD) improves when OCD symptoms improve, and whether (2) degree of insight in OCD predicts response to sertraline, data were obtained from five sites participating in a larger multisite study of relapse in OCD. During the first 16 weeks of the study, 71 patients received open-label treatment with sertraline and were assessed using the Yale-Brown Obsessive-Compulsive Rating Scale (Y-BOCS) and a rating scale to evaluate insight, the Brown Assessment of Beliefs Scale (BABS), at study baseline and termination. Baseline total BABS score was not significantly correlated with change in Y-BOCS score. Change in BABS total score and change in Y-BOCS total score were significantly correlated. There was no significant difference in mean endpoint Y-BOCS scores for patients with poor insight (n = 14) compared to patients with good insight at baseline (n = 57). Thus, insight improved with decrease in OCD symptom severity. Degree of insight at baseline did not predict response to sertraline, i.e., patients with poor insight were just as likely to respond to sertraline as patients with good insight.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a grant from Pfizer Pharmaceuticals, New York, NY.

PII: S0010-440X(01)47435-9

doi:10.1053/comp.2001.27898

Comprehensive Psychiatry
Volume 42, Issue 6 , Pages 494-497, November 2001